Corcept Therapeutics Inc (CORT) insider trading

Recent insider transactions reported to the SEC on Form 4 — directors and officers buying or selling their own company’s stock. Sourced directly from public SEC filings, latest filed Oct 5, 2026.

Get alerted when insiders buy the stocks you own

Add your holdings — no brokerage login — and Insider Radar sends a Telegram alert when an open-market Form 4 buy of $100,000 or more is filed on a stock you hold or watch.

Free for everyone right now · no card · nothing to buy

Start free
Filings shown
33
Open-market buys
0
Open-market sells
69

Counts cover the 33 most recent Form 4 filings Tradune holds for CORT (filed Jul 6 – Oct 5, 2026); the score below covers only the trailing 90 days (0 buys, 56 sells). No completed check of CORT's Form 4 list on SEC EDGAR is on record yet; the latest CORT filing Tradune holds was filed Oct 5, 2026. This is not guaranteed to be the complete record — see CORT's full Form 4 filing history on SEC EDGAR.

Open-market activity, last 90 days

Purchases (Form 4 code P) and sales (code S) on the 28 filings Tradune holds for CORT filed Aug 3 – Oct 5, 2026. Grants, exercises, tax withholding and the other Form 4 transaction codes are left out.

56 open-market sales by Rule 10b5-1 checkbox

On filings with the 10b5-1 box checked
53 sales· 416,523 sh
checkbox disclosed
On filings with the box not checked
3 sales· 38,225 sh
not proof that no plan exists
Not comparable
0 sales· 0 sh
filed before Apr 1, 2023, or no checkbox value in the filing data

Counts are Form 4 lines as filed. The checkbox is one per filing, so every sale on a filing with the box checked is counted there even if only some of its transactions were under a plan; it records what the filer disclosed, and the three categories are not a judgement about why a sale was made.

Open-market purchases and sales by insider
Insider Buys Sells Shares bought Shares sold Value
Atabak MokariChief Financial Officer 0 13 — 80,000 −$9,177,109
Sean MaduckOfficer (see filing) 0 11 — 105,955 −$12,521,293
Roberto Wandenkolk VieiraPresident, Oncology 0 11 — 66,962 −$7,458,056
Joseph Douglas LyonOfficer (see filing) 0 6 — 21,540 −$2,471,484
James N. WilsonDirector 0 6 — 20,000 −$2,221,201
David L. MahoneyDirector 0 4 — 103,606 −$12,251,411
William GuyerChief Development Officer 0 3 — 20,000 −$2,267,452
Kimberly ParkDirector 0 1 — 26,685 −$3,270,169
Gary Charles RobbChief Business Officer 0 1 — 10,000 −$1,162,572

Value = shares × the price reported on each Form 4 (+ purchases, − sales); every open-market line in this window disclosed a price.

Insider-activity score
0/ 100
Net insider sales
0 distinct buyers0 buy · 56 sell tx

Summarises ~90 days of public SEC Form 4 activity — more distinct buyers, officer involvement and net buying score higher. A description of filing activity, not a rating or buy signal. How this score is computed →

How to read this: an open-market purchase (Form 4 code P) is a buy at the market price with the insider’s own money, as opposed to a grant, award or option exercise; an open-market sale is code S. When two or more distinct insiders report open-market purchases in the same 90-day window, this site labels that a cluster — a definition, not a forecast; see insider cluster buying. “Held after” is Form 4 Table I column 5; “Change” = shares ÷ holdings before the trade (held after − shares for an acquisition, held after + shares for a disposition).

Insider Buying at CORT

No open-market insider purchases (Form 4 code P) were reported for CORT between Jul 6, 2026 and Oct 5, 2026. The filings below may include other transaction types — sales, grants, option exercises, and tax withholding — shown for completeness; they are not open-market purchases.

Recent Form 4 filings

Source: SEC EDGAR Form 4 · transaction codes explained

Roberto Wandenkolk Vieira President, Oncology · filed Oct 5, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise Stock option (right to buy) 8,333 — — — Oct 2, 2026
Open-market sale 10b5-1 box checked 5,147 $116.59 3,946 −57% Oct 2, 2026
Open-market sale 10b5-1 box checked 2,086 $115.73 9,093 −19% Oct 2, 2026
Open-market sale 10b5-1 box checked 1,100 $114.52 11,179 −9.0% Oct 2, 2026
Option exercise 8,333 $21.63 12,279 +211% Oct 2, 2026

† change in this filer’s own reported holding line (Form 4 Table I, col. 5), not of total company ownership; small prior holdings produce large percentages, so under 100 shares the prior holding is shown instead.

“10b5-1 box checked” = the filer checked the Form 4 box stating that a transaction on the filing was made under a plan intended to satisfy Rule 10b5-1(c); “10b5-1 box not checked” = the box was left blank, which does not prove that no plan exists. The box applies to Form 4s filed from April 1, 2023; older filings, and boxes we could not read, carry no tag. What the 10b5-1 box means.

Joseph Douglas Lyon Officer (see filing) · filed Oct 5, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise Stock option (right to buy) 5,833 — — — Oct 2, 2026
Option exercise Stock option (right to buy) 3,357 — — — Oct 2, 2026
Open-market sale 10b5-1 box checked 4,744 $116.54 5,683 −45% Oct 2, 2026
Open-market sale 10b5-1 box checked 4,446 $115.70 10,427 −30% Oct 2, 2026
Option exercise 5,833 $19.26 14,873 +65% Oct 2, 2026
Option exercise 3,357 $13.56 9,040 +59% Oct 2, 2026
Open-market sale 10b5-1 box checked 810 $115.40 5,683 −12% Oct 1, 2026
Option exercise Stock option (right to buy) 810 — — — Oct 1, 2026
Option exercise 810 $13.56 6,493 +14% Oct 1, 2026
Sean Maduck Officer (see filing) · filed Oct 5, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 8,744 $116.55 9,938 −47% Oct 2, 2026
Option exercise Stock option (right to buy) 24,587 — — — Oct 2, 2026
Option exercise 24,587 $8.27 34,525 +247% Oct 2, 2026
Open-market sale 10b5-1 box checked 15,843 $116.12 18,682 −46% Oct 2, 2026
Open-market sale 10b5-1 box checked 413 $115.54 9,938 −4.0% Oct 1, 2026
Option exercise 413 $8.27 10,351 +4.2% Oct 1, 2026
Option exercise Stock option (right to buy) 413 — — — Oct 1, 2026
Justin Frederick Gunn Officer (see filing) · filed Oct 5, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (right to buy) 100,000 — — — Oct 1, 2026
Gary Charles Robb Chief Business Officer · filed Sep 28, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Gift 5,000 — 20,571 (indirect) +32% Sep 24, 2026
Gift 17,100 — 14,056 −55% Sep 24, 2026
Gift 5,000 — 20,571 (indirect) +32% Sep 24, 2026
Gary Charles Robb Chief Business Officer · filed Sep 18, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise 17,493 $8.27 31,156 +128% Sep 17, 2026
Option exercise Stock option (right to buy) 17,493 — — — Sep 17, 2026
Roberto Wandenkolk Vieira President, Oncology · filed Sep 18, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 296 $100.82 3,946 −7.0% Sep 16, 2026
James N. Wilson Director · filed Sep 16, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 2,800 $111.70 1,064,543 (indirect) −0.3% Sep 15, 2026
Open-market sale 10b5-1 box checked 6,800 $110.27 1,067,743 (indirect) −0.6% Sep 15, 2026
Open-market sale 10b5-1 box checked 400 $110.84 1,067,343 (indirect) −0.0% Sep 15, 2026
Joseph Douglas Lyon Officer (see filing) · filed Sep 16, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise Stock option (right to buy) 2,596 — — — Sep 14, 2026
Open-market sale 10b5-1 box checked 2,188 $114.12 5,683 −28% Sep 14, 2026
Option exercise Stock option (right to buy) 7,404 — — — Sep 14, 2026
Option exercise 2,596 $11.35 8,279 +46% Sep 14, 2026
Option exercise 7,404 $13.56 15,683 +89% Sep 14, 2026
Open-market sale 10b5-1 box checked 7,812 $113.32 7,871 −50% Sep 14, 2026
Sean Maduck Officer (see filing) · filed Sep 3, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Tax withholding 117 $113.38 9,938 −1.2% Sep 2, 2026
Open-market sale 10b5-1 box checked 10,989 $114.71 12,036 −48% Sep 1, 2026
Option exercise 25,000 $8.27 34,755 +256% Sep 1, 2026
Open-market sale 10b5-1 box checked 11,730 $113.94 23,025 −34% Sep 1, 2026
Open-market sale 10b5-1 box checked 2,281 $115.61 9,755 −19% Sep 1, 2026
Grant / award 150 $113.38 9,905 +1.5% Sep 1, 2026
Grant / award 150 — 10,055 +1.5% Sep 1, 2026
Option exercise Stock option (right to buy) 25,000 — — — Sep 1, 2026
Atabak Mokari Chief Financial Officer · filed Sep 3, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Tax withholding 102 $113.38 16,304 −0.6% Sep 2, 2026
Grant / award 138 $113.38 16,268 +0.9% Sep 1, 2026
Grant / award 138 — 16,406 +0.8% Sep 1, 2026
Gary Charles Robb Chief Business Officer · filed Sep 3, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Tax withholding 91 $113.38 13,663 −0.7% Sep 2, 2026
Grant / award 164 $113.38 13,590 +1.2% Sep 1, 2026
Grant / award 164 — 13,754 +1.2% Sep 1, 2026
Roberto Wandenkolk Vieira President, Oncology · filed Sep 3, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 23,770 $110.70 15,205 −61% Sep 2, 2026
Open-market sale 10b5-1 box checked 1,537 $111.37 13,668 −10% Sep 2, 2026
Open-market sale 10b5-1 box checked 974 $112.40 12,694 −7.1% Sep 2, 2026
Open-market sale 10b5-1 box checked 1,606 $113.72 11,088 −13% Sep 2, 2026
Open-market sale 10b5-1 box checked 5,621 $114.58 5,467 −51% Sep 2, 2026
Open-market sale 10b5-1 box checked 1,225 $115.44 4,242 −22% Sep 2, 2026
Option exercise Stock option (right to buy) 58,333 — — — Sep 2, 2026
Tax withholding 102 $113.38 4,242 −2.3% Sep 2, 2026
Option exercise 58,333 $21.63 62,575 +1,375% Sep 2, 2026
Open-market sale 10b5-1 box checked 23,600 $109.35 38,975 −38% Sep 2, 2026
Grant / award 138 $113.38 4,206 +3.4% Sep 1, 2026
Grant / award 138 — 4,344 +3.3% Sep 1, 2026
Joseph Douglas Lyon Officer (see filing) · filed Sep 3, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Tax withholding 72 $113.38 5,683 −1.3% Sep 2, 2026
Grant / award 130 $113.38 5,625 +2.4% Sep 1, 2026
Grant / award 130 — 5,755 +2.3% Sep 1, 2026
William Guyer Chief Development Officer · filed Sep 3, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award 164 $113.38 4,149 +4.1% Sep 1, 2026
Grant / award 164 — 4,313 +4.0% Sep 1, 2026
Kimberly Park Director · filed Aug 28, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Tax withholding 3,315 $122.09 26,685 −11% Aug 26, 2026
Open-market sale 10b5-1 box not checked 26,685 $122.55 0 −100% Aug 26, 2026
Option exercise 30,000 $13.49 30,000 — Aug 26, 2026
Option exercise Stock Option (right to buy) 30,000 — — — Aug 26, 2026
Sean Maduck Officer (see filing) · filed Aug 27, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 5,870 $126.06 9,755 −38% Aug 25, 2026
Open-market sale 10b5-1 box checked 25,085 $125.47 15,625 −62% Aug 25, 2026
Option exercise Stock option (right to buy) 30,955 — — — Aug 25, 2026
Option exercise 30,955 $11.35 40,710 +317% Aug 25, 2026
David L. Mahoney Director · filed Aug 20, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 7,055 $118.88 1,133,939 (indirect) −0.6% Aug 18, 2026
Open-market sale 10b5-1 box checked 4,984 $117.47 1,232,161 (indirect) −0.4% Aug 18, 2026
Open-market sale 10b5-1 box checked 400 $119.64 1,133,539 (indirect) −0.0% Aug 18, 2026
Open-market sale 10b5-1 box checked 91,167 $118.24 1,140,994 (indirect) −7.4% Aug 18, 2026
Gary Charles Robb Chief Business Officer · filed Aug 18, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Gift 125 — 13,426 −0.9% Aug 17, 2026
Open-market sale 10b5-1 box not checked 10,000 $116.26 39,716 (indirect) −20% Aug 17, 2026
Sean Maduck Officer (see filing) · filed Aug 18, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise 3,664 $8.27 13,419 +38% Aug 14, 2026
Open-market sale 10b5-1 box checked 3,664 $114.49 9,755 −27% Aug 14, 2026
Option exercise Stock option (right to buy) 3,664 — — — Aug 14, 2026
James N. Wilson Director · filed Aug 18, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 2,279 $112.64 1,074,543 (indirect) −0.2% Aug 14, 2026
Open-market sale 10b5-1 box checked 3,053 $110.49 1,081,490 (indirect) −0.3% Aug 14, 2026
Open-market sale 10b5-1 box checked 4,668 $111.44 1,076,822 (indirect) −0.4% Aug 14, 2026
Gary Charles Robb Chief Business Officer · filed Aug 14, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Gift 3,000 — 15,571 (indirect) +24% Aug 12, 2026
Gift 3,000 — 15,571 (indirect) +24% Aug 12, 2026
Gift 11,530 — 13,551 −46% Aug 12, 2026
Sean Maduck Officer (see filing) · filed Aug 12, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise Stock option (right to buy) 1,031 — — — Aug 10, 2026
Option exercise 1,031 $8.27 10,786 +11% Aug 10, 2026
Open-market sale 10b5-1 box checked 1,031 $114.52 9,755 −9.6% Aug 10, 2026
William Guyer Chief Development Officer · filed Aug 12, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise Stock Option (right to buy) 16,300 — — — Aug 10, 2026
Open-market sale 10b5-1 box checked 4,770 $114.04 3,985 −54% Aug 10, 2026
Open-market sale 10b5-1 box checked 11,530 $113.18 8,755 −57% Aug 10, 2026
Option exercise 16,300 $21.65 20,285 +409% Aug 10, 2026
William Guyer Chief Development Officer · filed Aug 6, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Option exercise 3,700 $21.65 7,685 +93% Aug 4, 2026
Open-market sale 10b5-1 box checked 3,700 $113.12 3,985 −48% Aug 4, 2026
Option exercise Stock Option (right to buy) 3,700 — — — Aug 4, 2026

Listing the 25 most recent of 33 Form 4 filings held for CORT; the 8 older filings (filed Jul 6 – Aug 5, 2026) are counted above but not listed here — see CORT's full Form 4 filing history on SEC EDGAR.

Insider filings reported around the same time

Other companies whose most recent Form 4 was filed closest to CORT's (Oct 5, 2026).

Frequently asked about CORT insider activity

How many insiders bought CORT stock in these Form 4 filings?

No open-market purchases (Form 4 code P) of CORT shares were reported by Corcept Therapeutics Inc insiders between Jul 6, 2026 and Oct 5, 2026. The 33 filings shown on this page cover other transaction types — sales, grants, option exercises, and tax withholding.

Who filed the most recent Form 4 for CORT?

The most recent Form 4 on this page was filed by Justin Frederick Gunn (Officer (see filing)) on Oct 5, 2026, reporting 1 transaction. The original document is linked from the filing list above on SEC EDGAR. Amended filings (Form 4/A) may later revise reported figures.

What was the largest open-market CORT insider sale shown?

The largest open-market sale among the filings shown was 91,167 CORT shares at $118.24 (about $10,779,367) by David L. Mahoney (Director) on Aug 18, 2026. Value is shares × the price reported on the Form 4; that Form 4 has the Rule 10b5-1 box checked.

New to Form 4s? The transaction codes, the 90-day window and the 0–100 score are defined on the insider-activity score methodology page.

Get insider alerts for CORT — and your whole portfolio

Tradune watches SEC Form 4 filings and flags insider-cluster buying across everything you hold, routed to you automatically. Free for everyone right now · no card · nothing to buy

Track CORT insider filings free →

This score summarizes SEC Form 4 filing activity over the trailing 90 days. It is descriptive, not predictive — not a rating, recommendation, or investment advice. Data: SEC EDGAR (public domain), as filed; amendments may revise figures. Tradune is not a registered investment adviser.

Data as filed; amended filings (Form 4/A) may revise figures. Sales may occur under prearranged Rule 10b5-1 trading plans.